Core Viewpoint - MicroPort Robotics-B experienced a significant stock price increase, with a rise of over 24% in early trading, reaching a peak of 26.48 HKD per share, and maintaining a strong performance at 26.16 HKD per share as of 10:38 AM [1]. Group 1 - The company announced that the cumulative order volume for its core products, including endoscopic, orthopedic, and vascular intervention devices, has surpassed 230 units [3]. - The commercial orders for the core product, the TUMAI endoscopic surgical robot, have exceeded 160 units globally, with nearly 120 new orders acquired this year [3]. - The company has completed over 150 commercial installations across its various products [3]. Group 2 - The company’s self-developed bronchoscopic surgical robot, the UniPathTM electronic bronchoscopic navigation system, has officially received approval from the National Medical Products Administration [4]. - This approval represents a milestone breakthrough in the field of surgical robotics, indicating a comprehensive coverage of key technological pathways for minimally invasive diagnosis and treatment in domestic surgical robots [4].